- Home
- EXAS vs BXSL Comparison
EXAS vs BXSL Comparison
Compare EXAS & BXSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- BXSL
- Stock Information
- Founded
- EXAS 1995
- BXSL 2018
- Country
- EXAS United States
- BXSL United States
- Employees
- EXAS N/A
- BXSL N/A
- Industry
- EXAS Medical Specialities
- BXSL Trusts Except Educational Religious and Charitable
- Sector
- EXAS Health Care
- BXSL Finance
- Exchange
- EXAS Nasdaq
- BXSL Nasdaq
- Market Cap
- EXAS 9.1B
- BXSL 7.3B
- IPO Year
- EXAS N/A
- BXSL N/A
- Fundamental
- Price
- EXAS $45.60
- BXSL $29.81
- Analyst Decision
- EXAS Strong Buy
- BXSL Buy
- Analyst Count
- EXAS 22
- BXSL 5
- Target Price
- EXAS $66.43
- BXSL $31.25
- AVG Volume (30 Days)
- EXAS 3.9M
- BXSL 967.8K
- Earning Date
- EXAS 08-06-2025
- BXSL 08-06-2025
- Dividend Yield
- EXAS N/A
- BXSL 10.34%
- EPS Growth
- EXAS N/A
- BXSL N/A
- EPS
- EXAS N/A
- BXSL 2.83
- Revenue
- EXAS $2,939,949,000.00
- BXSL $1,398,444,000.00
- Revenue This Year
- EXAS $14.61
- BXSL $9.58
- Revenue Next Year
- EXAS $12.71
- BXSL $3.71
- P/E Ratio
- EXAS N/A
- BXSL $10.54
- Revenue Growth
- EXAS 12.55
- BXSL 14.70
- 52 Week Low
- EXAS $38.81
- BXSL $25.89
- 52 Week High
- EXAS $72.83
- BXSL $34.64
- Technical
- Relative Strength Index (RSI)
- EXAS 44.47
- BXSL 30.06
- Support Level
- EXAS $40.55
- BXSL $29.85
- Resistance Level
- EXAS $45.45
- BXSL $30.69
- Average True Range (ATR)
- EXAS 2.04
- BXSL 0.47
- MACD
- EXAS 0.07
- BXSL -0.17
- Stochastic Oscillator
- EXAS 63.10
- BXSL 4.20
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.